Clinical Drug Experience Knowledgebase

babaodan (1 trial)

carvedilol (coreg) (2 trials)

cidan (1 trial)

cisatracurium (nimbex) (1 trial)

metuximab (2 trials)

nadroparin (1 trial)

rocuronium (zemuron) (1 trial)

vecuronium (norcuron) (1 trial)

warfarin (coumadin) (1 trial)

xihuang (1 trial)

bortezomib (velcade) (1 trial)

cisplatin (platinol) (2 trials)

eadm (5 trials)

enoxaparin (lovenox) (1 trial)

epirubicin (ellence) (4 trials)

fluorouracil (efudex) (9 trials)

gelatin (1 trial)

indomethacin (indocin) (1 trial)

leucovorin (4 trials)

lipiodol (3 trials)

somatostatin (2 trials)

anlotinib (1 trial)

apatinib (1 trial)

autologous tumor infiltrating lymphocytes (1 trial)

carboplatin (paraplatin) (1 trial)

cd19 car-t cells (1 trial)

cetuximab (erbitux) (2 trials)

crizotinib (xalkori) (2 trials)

dendritic cell-precision multiple antigen t cells (3 trials)

dendritic cells (1 trial)

docetaxel (taxotere) (1 trial)

endostatin (endostar) (1 trial)

everolimus (zortress) (2 trials)

gefitinib (iressa) (2 trials)

gemcitabine (gemzar) (3 trials)

irinotecan (Camptosar) (2 trials)

lapatinib (tykerb) (2 trials)

mitomycin (mutamycin) (1 trial)

oxaliplatin (eloxatin) (4 trials)

pertuzumab (perjeta) (1 trial)

pik-her2 cell (1 trial)

pik-pd-1 cells (1 trial)

precision multiple antigen t cell (1 trial)

sorafenib (nexavar) (3 trials)

tegafur (2 trials)

toripalimab (1 trial)

trastuzumab (herceptin) (3 trials)

tumor-pulsed dendritic cells (1 trial)

s-adenosyl methionine (1 trial)

sirolimus (rapamune) (1 trial)

chtnt-1 (1 trial)

entecavir (baraclude) (1 trial)

gimeracil (1 trial)

ginsenoside rg3 (3 trials)

glycyrrhizin (1 trial)

oteracil (1 trial)

pregabalin (lyrica) (1 trial)

therarubicin (1 trial)

ulinastatin (1 trial)

urea (1 trial)